KPMG’s new report Growing the pipeline, growing the bottom line: Shifts in pharmaceutical R&D innovation looks at the research challenge through the eyes of senior R&D executives from some of the world’s leading pharma companies. Their responses suggest:
- pharmaceutical R&D innovation is on the rise, with 70 percent of respondents believing their companies are enjoying a resurgence in research productivity
- organizational barriers to R&D innovation persist: 72 percent of respondents claim that excessive administrative work prevents scientists from devoting time to research
- pharmaceutical R&D outsourcing and collaboration is set to continue, with an increasing proportion of research budgets now spent externally.
- Balance governance and administrative burdens with project size and complexity, giving scientists space to engage in R&D.
- Strengthen collaboration and alliances – particularly with universities – and adapt R&D to support innovation across networks.
- Align Commercial, Finance and R&D operations to more rigorously challenge research objectives and focus on the return on investment (ROI).
- Bring the customer and patient to the heart of R&D; assessing the value of a project in terms of outcomes and improved quality of life.
- Develop an environment that attracts and retains world-class scientists.